JE
LeonaBio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lasofoxifene | ER+, HER2-negative, ESR1-mutated metastatic breast cancer | Phase 3 |
| ATH-1105 | Amyotrophic Lateral Sclerosis (ALS) | Phase 1 (inferred) |
| ATH-1020 | Undisclosed (Neurology) | Undisclosed |
| Fosgonimeton | Undisclosed (likely neurodegenerative) | Undisclosed |
Leadership Team at LeonaBio
ML
Mark Litton, PhD
President & Chief Executive Officer
JS
Javier San Martin, M.D.
Chief Medical Officer
KC
Kevin Church, PhD
Chief Scientific Officer
MW
Mark Worthington, JD
General Counsel, Chief Compliance Officer, & Corporate Secretary
RR
Robert Renninger
Chief Financial Officer
KR
Kelly Romano
Chair of the Board of Directors